Keros Therapeutics, Inc. Common Stock | KROS

Daily Technical Analysis of Keros Therapeutics, Inc. Common Stock

Keros Therapeutics had a nice pop today and is currently up 5.13% -- which is pretty good. Investors have a more positive outlook for the company and future revenue. It looks like KROS may be interacting with a slightly angled support line. This area could represent a pivot point that it moves up from. In addition to being near an angled support line KROS is near a weak support line. We'll see if it bounces off or heads lower. Keros Therapeutics hasn't been treated too well by the market over the last few months and has seen a lot of selling continue to drive price down. It might get a little bounce here and that may be subsequently followed by profit taking. Over the past 3 months, owners of the asset are down -35.81 percent, we'll see if more buyers feel it's appropriately priced and want to purchase, if so we might get a little bounce.

If we get a reversal off of support and Keros Therapeutics starts moving up, it can probably get to $11.93 at which point it'll need to break through that resistance level in order to keep moving higher. If Keros Therapeutics continues to break down lower from here, it'll likely fall until it gets to $10.15 at which point previous buyers at this level may move in and give it support.

Analyst Ratings for Keros Therapeutics By Price Target And Rating

The analysts are pretty neutral on Keros Therapeutics right now, so not much useful information here. The current Analysts Sentiment Score is 2.93. Most companies range between (-200 to 200).

Here's a break down of the latest rating changes. On 2024-03-01 HC Wainwright reiterated their rating of Buy and added a price target of $100.00. On 2024-02-29 there was confirmation of the previous rating by Wedbush which was Outperform and provided a price target of $86.00. William Blair reiterated a rating of Outperform on 2024-02-21. On 2023-12-08 Wells Fargo & Company initiated their coverage and rated as Overweight and they set their price target at $60.00.Bank of America announced that they are initiating coverage with a rating of Buy on 2023-07-26 and added a price target of $65.00. Piper Sandler announced a lowering of their price target to $110.00 from $120.00 on 2023-05-05.

Earnings Per Share (EPS) Estimates By Year and Quarter

Short interest for Keros Therapeutics

We take into account several different measures of short interest to create a composite score. These measures are shown in the chart below. Short selling is when investors are betting against a stock. We compile these factors to create a dynamic Short Score - this can indicate poor sentiment, internal problems with a company or industry and the anticipation of future price declines. We look at the short interest percent, days to cover, the rate of change and total shares sold short.

Social Sentiment for Keros Therapeutics

Social Sentiment is an aggregation of several different factors such as news, articles, blogs, user content, ratings, etc. Which is shown in the chart below. It may become predictive of a reversal if price and the sentiment diverge. Broader market forces may push prices up or down but if market participants maintain a different view on a specific stock, it may be taken as an opportunity to buy or sell in those cases.